Sarepta Therapeutics, Inc. - Product Pipeline Review - 2016

1 of 4
Sarepta Therapeutics, Inc. - Product Pipeline Review - 2016

Summary

‘Sarepta Therapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the Sarepta Therapeutics, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sarepta Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Sarepta Therapeutics, Inc.
- The report provides overview of Sarepta Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Sarepta Therapeutics, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Sarepta Therapeutics, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Sarepta Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sarepta Therapeutics, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sarepta Therapeutics, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Sarepta Therapeutics, Inc. Snapshot

Sarepta Therapeutics, Inc. Overview

Key Information

Key Facts

Sarepta Therapeutics, Inc. - Research and Development Overview

Key Therapeutic Areas

Sarepta Therapeutics, Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Sarepta Therapeutics, Inc. - Pipeline Products Glance

Sarepta Therapeutics, Inc. - Late Stage Pipeline Products

Pre-Registration Products/Combination Treatment Modalities

Sarepta Therapeutics, Inc. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Sarepta Therapeutics, Inc. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Sarepta Therapeutics, Inc. - Drug Profiles

eteplirsen

Product Description

Mechanism of Action

R&D Progress

SRP-4053

Product Description

Mechanism of Action

R&D Progress

SRP-4045

Product Description

Mechanism of Action

R&D Progress

AVI-7288

Product Description

Mechanism of Action

R&D Progress

radavirsen

Product Description

Mechanism of Action

R&D Progress

Antisense Oligonucleotide to Inhibit AcpP for Burkholderia Cepacia Infections

Product Description

Mechanism of Action

R&D Progress

Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD

Product Description

Mechanism of Action

R&D Progress

PMO-25

Product Description

Mechanism of Action

R&D Progress

SRP-4008

Product Description

Mechanism of Action

R&D Progress

SRP-4044

Product Description

Mechanism of Action

R&D Progress

SRP-4050

Product Description

Mechanism of Action

R&D Progress

SRP-4052

Product Description

Mechanism of Action

R&D Progress

SRP-4055

Product Description

Mechanism of Action

R&D Progress

Antisense Oligonucleotide 1 to Activate Dystrophin for Duchenne Muscular Dystrophy

Product Description

Mechanism of Action

R&D Progress

Antisense Oligonucleotide for Acinetobacter baumannii Infections

Product Description

Mechanism of Action

R&D Progress

Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections

Product Description

Mechanism of Action

R&D Progress

Antisense Oligonucleotide for Drug Resistant Pseudomonas Aeruginosa Infections

Product Description

Mechanism of Action

R&D Progress

Antisense Oligonucleotide for Methicillin Resistant Staphylococcus Aureus Infections

Product Description

Mechanism of Action

R&D Progress

Antisense Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy

Product Description

Mechanism of Action

R&D Progress

Antisense Oligonucleotide to Activate Lamin A for Progeria

Product Description

Mechanism of Action

R&D Progress

Antisense Oligonucleotide to Activate Lysosomal Alpha-Glucosidase for Pompe Disease

Product Description

Mechanism of Action

R&D Progress

Antisense Oligonucleotide to Inhibit DM1 Protein Kinase for Myotonic Dystrophy

Product Description

Mechanism of Action

R&D Progress

Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections

Product Description

Mechanism of Action

R&D Progress

Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease

Product Description

Mechanism of Action

R&D Progress

Antisense Oligonucleotides for Infectious Diseases

Product Description

Mechanism of Action

R&D Progress

Bacterial PPMO

Product Description

Mechanism of Action

R&D Progress

Viral PMO-X

Product Description

Mechanism of Action

R&D Progress

Sarepta Therapeutics, Inc. - Pipeline Analysis

Sarepta Therapeutics, Inc. - Pipeline Products by Target

Sarepta Therapeutics, Inc. - Pipeline Products by Route of Administration

Sarepta Therapeutics, Inc. - Pipeline Products by Molecule Type

Sarepta Therapeutics, Inc. - Pipeline Products by Mechanism of Action

Sarepta Therapeutics, Inc. - Recent Pipeline Updates

Sarepta Therapeutics, Inc. - Dormant Projects

Sarepta Therapeutics, Inc. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

AVI-4065

AVI-6002

AVI-7537

Sarepta Therapeutics, Inc. - Company Statement

Sarepta Therapeutics, Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 73List of Tables

Sarepta Therapeutics, Inc., Key Information

Sarepta Therapeutics, Inc., Key Facts

Sarepta Therapeutics, Inc. - Pipeline by Indication, 2016

Sarepta Therapeutics, Inc. - Pipeline by Stage of Development, 2016

Sarepta Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016

Sarepta Therapeutics, Inc. - Pre-Registration, 2016

Sarepta Therapeutics, Inc. - Phase II, 2016

Sarepta Therapeutics, Inc. - Phase I, 2016

Sarepta Therapeutics, Inc. - Preclinical, 2016

Sarepta Therapeutics, Inc. - Discovery, 2016

Sarepta Therapeutics, Inc. - Pipeline by Target, 2016

Sarepta Therapeutics, Inc. - Pipeline by Route of Administration, 2016

Sarepta Therapeutics, Inc. - Pipeline by Molecule Type, 2016

Sarepta Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016

Sarepta Therapeutics, Inc. - Recent Pipeline Updates, 2016

Sarepta Therapeutics, Inc. - Dormant Developmental Projects,2016

Sarepta Therapeutics, Inc. - Discontinued Pipeline Products, 2016

Sarepta Therapeutics, Inc., Other Locations

Sarepta Therapeutics, Inc., Subsidiaries 71List of Figures

Sarepta Therapeutics, Inc. - Pipeline by Top 10 Indication, 2016

Sarepta Therapeutics, Inc. - Pipeline by Stage of Development, 2016

Sarepta Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016

Sarepta Therapeutics, Inc. - Pipeline by Top 10 Target, 2016

Sarepta Therapeutics, Inc. - Pipeline by Route of Administration, 2016

Sarepta Therapeutics, Inc. - Pipeline by Molecule Type, 2016

Sarepta Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll